Nagaoka, K., Shirai, M., Taniguchi, K., Hosoi, A., Sun, C., Kobayashi, Y., . . . Kakimi, K. (2020). Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy. J Immunother Cancer.
Styl ChicagoNagaoka, Koji, et al. "Deep Immunophenotyping At the Single-cell Level Identifies a Combination of Anti-IL-17 and Checkpoint Blockade As an Effective Treatment in a Preclinical Model of Data-guided Personalized Immunotherapy." J Immunother Cancer 2020.
Citace podle MLANagaoka, Koji, et al. "Deep Immunophenotyping At the Single-cell Level Identifies a Combination of Anti-IL-17 and Checkpoint Blockade As an Effective Treatment in a Preclinical Model of Data-guided Personalized Immunotherapy." J Immunother Cancer 2020.